Table 2. Clinical details of autoimmune LE patients (acute phase).
| Code | Age (years) | Sex | Antibody type | Acute T2 scan notes | ||
|---|---|---|---|---|---|---|
| HPC | Other structures | |||||
| R | L | |||||
| 1 | 65.75 | M | LGI1 | Normal T2 signal and volume; facilitated diffusion | High T2 signal; swelling; normal diffusion | L AMG: high T2 signal |
| 2 | 69.98 | F | VGKCC | Normal T2 signal; mild atrophy; facilitated diffusion | High T2 signal; normal volume; facilitated diffusion | No abnormalities |
| 3 | 62.23 | M | VGKCC | Normal T2 signal and volume; facilitated diffusion | High T2 signal; swelling; normal diffusion | L AMG, L ERC: high T2 signal |
| 4 | 46.41 | M | LGI1 | High T2 signal; normal volume; normal diffusion | Normal T2 signal and volume; facilitated diffusion | No abnormalities |
| 5 | 56.65 | M | LGI1 | L/R: high T2 signal | No abnormalities | |
| 6 | 58.18 | M | LGI1 | No abnormalities | ||
| 7 | 56.13 | M | LGI1 | Normal volume and signal | High T2 signal; swelling | L/R AMG: high T2 signal |
| 8 | 76.54 | M | LGI1 | High T2 signal; normal volume and diffusion | High T2 signal; normal volume; facilitated diffusion | No abnormalities |
| 9 | 54.94 | M | LGI1 | High T2 signal; swelling; normal diffusion | High T2 signal; swelling; normal diffusion | No abnormalities |
| 10 | 44.81 | M | LGI1 | L/R: high T2 signal; swelling | No abnormalities | |
| 11 | 45.77 | M | LGI1 | High T2 signal; normal volume | High T2 signal; normal volume | No abnormalities |
| 12 | 46.06 | M | LGI1/Caspr2 | High T2 signal; atrophy | Normal T2 signal and volume | No abnormalities |
| 13 | 35.75 | M | LGI1/Caspr2 | L/R: normal T2 signal; mild atrophy; normal diffusion | No abnormalities | |
| 14 | 72.08 | M | LGI1 | High T2 signal; mild atrophy; facilitated diffusion | Normal T2 signal; atrophy; facilitated diffusion | No abnormalities |
| 15 | 52.28 | M | LGI1 | High T2 signal; normal volume; facilitated diffusion | Normal T2 signal and volume; facilitated diffusion | No abnormalities |
| 16 | 52.48 | M | LGI1/Caspr2 | High T2 signal; swelling; facilitated diffusion | Normal T2 signal and volume; facilitated diffusion | No abnormalities |
| 17 | 51.62 | M | VGKCC | High T2 signal; swelling | Normal T2 signal and volume | No abnormalities |
| 18 | 75.18 | M | LGI1 | L/R: high T2 signal; swelling; normal diffusion | L/R AMG: high T2 signal; swelling | |
| 19 | 78.73 | M | LG1/Caspr2 | High T2 signal; mild atrophy; normal diffusion | High T2 signal; normal volume; normal diffusion | No abnormalities |
| 20 | 53.75 | F | LGI1 | L/R: high T2 signal; normal volume and diffusion | No abnormalities | |
| 21 | 73.68 | F | VGKCC | L/R: high T2 signal; swelling; facilitated diffusion | No abnormalities | |
| 22 | 63.59 | M | LGI1 | L/R: high T2 signal; normal volume and diffusion | No abnormalities | |
| 23 | 60.35 | M | VGKCC | No abnormalities | ||
| 24 | 54.30 | M | VGKCC | L/R: high T2 signal; atrophy | L/R AMG: high T2 signal; atrophy | |
| 25 | 52.70 | M | seronegative | L/R: high T2 signal | No abnormalities | |
| 26 | 47.43 | F | seronegative | No abnormalities | ||
| 27 | 58.60 | M | seronegative | L/R: high T2 signal | No abnormalities | |
| 28 | 25.42 | M | Anti-Ma2 | L/R: high T2 signal and swelling | No abnormalities | |
| 29 | 45.77 | F | seronegative | L/R: high T2 signal | No abnormalities | |
| 30 | 16.64 | F | GAD | No abnormalities | ||
| 31 | 71.35 | M | seronegative | L/R: high T2 signal; atrophy | No abnormalities | |
| 32 | 60.44 | M | VGKCC | L/R: atrophy | PHC atrophy | |
| 33 | 53.48 | M | seronegative | L/R: atrophy | No abnormalities | |
| 34 | 64.87 | F | seronegative | L/R: atrophy | No abnormalities | |
| 35 | 47.32 | F | seronegative | L/R: high T2 signal | R AMG: high T2 signal; swelling | |
| 36 | 61.88 | F | seronegative | L/R: high T2 signal; atrophy | No abnormalities | |
| 37 | 71.90 | F | seronegative | L/R: high T2 signal (especially R) | No abnormalities | |
| 38 | 34.49 | F | GAD | L/R: high T2 signal | No abnormalities | |
Age: age at symptom onset (years); AMG: Amygdala; Caspr2: anti-contactin-associated protein-like 2; ERC: entorhinal cortex; F = female; GAD: anti-glutamic acid decarboxylase autoantibody; HPC: hippocampus; L: left hemisphere; LGI1: anti-leucine-rich glioma-inactivated1; M = male; PHC: parahippocampal cortex; R: right hemisphere; VGKCC: anti-voltage-gated potassium channel complex. The clinical details of patients 1–24 have also been presented in Loane et al. (2019).